Stevens Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Stevens Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,980	Closed	-$273K	–	1046
2018 Q2	$273K	Buy	+13,980	New	+$309K	0.01%	650
2018 Q1	–	Sell	-18,950	Closed	-$251K	–	1071
2017 Q4	$251K	Sell	18,950 -7,134	-27%	-$108K	0.01%	697
2017 Q3	$481K	Buy	+26,084	New	+$486K	0.02%	564
2016 Q4	–	Sell	-24,849	Closed	-$609K	–	1182
2016 Q3	$609K	Buy	+24,849	New	+$621K	0.03%	531
2016 Q2	–	Sell	-48,719	Closed	-$1.14M	–	1196
2016 Q1	$1.14M	Buy	+48,719	New	+$1.16M	0.05%	398
2015 Q4	–	Sell	-22,562	Closed	-$896K	–	1231
2015 Q3	$896K	Buy	22,562 +19,183	+568%	+$1.19M	0.04%	376
2015 Q2	$233K	Buy	+3,379	New	+$213K	0.01%	827

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stevens Capital Management's AMAG Position: Q3 2018 in Review

Stevens Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2018, closing a stake of 13,980 shares — an estimated $273K sold.

Stevens Capital Management first reported a position in AMAG in Q2 2015 and held it in 7 quarters. The position peaked at $1.14M in Q1 2016. 182 funds tracked by Wall St. Rank hold AMAG as of Q3 2018.

Stevens Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Stevens Capital Management sold 13,980 AMAG Pharmaceuticals shares in Q3 2018, an estimated $273K.
Stevens Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Stevens Capital Management's AMAG Pharmaceuticals position peaked at $1.14M in Q1 2016.
182 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2018.

Based on Stevens Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.